Drugs / Xiaopi granules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06154109 | Nov 2023 → Dec 2025 | triple-negative breast carcinoma | Zhiyu Wang | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xiaopi granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154109 ↗ |
| Action | Inhibit | “Xiaopi Granules can inhibit tumor progression by targeting TAMs/CXCL1 signaling” NCT06154109 ↗ |
| Route | Oral | “participants will be subjected to Xiaopi granules or decoction orally” NCT06154109 ↗ |
| Target | CXCL1 | “Xiaopi Granules can inhibit tumor progression by targeting TAMs/CXCL1 signaling to suppress chemotherapy-induced autophagy” NCT06154109 ↗ |